Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Tolvaptan is a new drug that specifically antagonizes the V2-receptor of antidiuretic hormone
(ADH) and leads to water diuresis: During acute administration of tolvaptan, the main fear is
to induce a too fast increase in plasma sodium concentration and in turn brain damageHowever,
the tolvaptan-induced increase in plasma sodium concentration is expected to stimulate
thirst, preventing major negative water balance.
The investigators hypothesize that tolvaptan-induced increase in plasma osmolality (and
sodium concentration) is dependent of thirst adaptation that is influenced by physiological
factors, namely age and sex. To address the effect of a single oral administration of
tolvaptan at a dosage used during hyponatremia (15 mg) under free water access in healthy
volunteers. Primary outcome will be the maximal change in serum sodium concentration within
the 6 hours following tolvaptan administration.